Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1696.967 - 1721.419 Dr. Bogdana Schmidt

And I know there are ways to get our patients what we think is in their best interest. But even with all of this immunotherapy data, When patients didn't get cisplatin up front, we're still sort of advocating for cisplatin adjuvately because that's what we have the strongest longitudinal data for. So I'm sure that space will continue to evolve. Now, you almost led me straight to the...